EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Roles and potential applications of non-coding RNAs in cancer treatment with immune checkpoint inhibitors and immunomodulatory therapies

Yayu Chen, Zhishuang Ye, Yanping Wang, Shanlan Liang, Daniel Xin Zhang

Cancer Drug Resistance · 15.04.2026

DOI: 10.20517/cdr.2025.213 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Drug Resistance, online erschienen am 15.04.2026. Verfasst von Yayu Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, Hong Kong Metropolitan University, Hong Kong, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 246 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-coding RNAs (ncRNAs) have emerged as key regulators of cancer–immune crosstalk, especially in an era when immune checkpoint inhibitors and other immunomodulatory therapies are reshaping the cancer treatment landscape. Accumulating evidence continues to indicate that ncRNAs, including microRNAs, long non-coding RNAs and circular RNAs, critically connect oncological signaling with immune interactions, thereby influencing clinical outcomes. In this review, we summarize how ncRNAs modulate key immune checkpoint axes, particularly programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4). We also discuss ncRNA networks that are actively involved in modern cancer immunotherapies, such as T cell–based therapies, macrophage and dendritic cell engineering, cytokine therapies, cancer vaccines and oncolytic viruses. Building on these mechanistic insights, we outline the potential of ncRNAs as biomarkers for predicting response and prognosis, as future therapeutic targets to improve and enhance immunotherapy combinations, along with key barriers in the field and emerging solutions. Altogether, the evidence not only highlights ncRNAs as rising stars in precision immuno-oncology, but also motivates future opportunities to incorporate ncRNAs into clinical consideration.

Schlagwörter

Stichwörter der Autor:innen

Non-coding RNAcancerimmune checkpoint inhibitorsimmunotherapytherapy

Autor:innen und Institutionen

  • Department of Health Sciences, Hong Kong Metropolitan University, Hong Kong, China.
  • School of Nursing and Health Sciences, Hong Kong Metropolitan University, Hong Kong, China.
  • Hong Kong Metropolitan University Shenzhen Research Institute, Shenzhen 518057, Guangdong, China.

Zitieren

APA

Chen, Y., Ye, Z., Wang, Y., Liang, S., & Zhang, D. X. (2026). Roles and potential applications of non-coding RNAs in cancer treatment with immune checkpoint inhibitors and immunomodulatory therapies. Cancer Drug Resistance. https://doi.org/10.20517/cdr.2025.213

Vancouver

Chen Y, Ye Z, Wang Y, Liang S, Zhang DX. Roles and potential applications of non-coding RNAs in cancer treatment with immune checkpoint inhibitors and immunomodulatory therapies. Cancer Drug Resistance. 2026. doi:10.20517/cdr.2025.213

BibTeX
@article{Chen2026,
  author = {Chen, Yayu and Ye, Zhishuang and Wang, Yanping and Liang, Shanlan and Zhang, Daniel Xin},
  title = {Roles and potential applications of non-coding RNAs in cancer treatment with immune checkpoint inhibitors and immunomodulatory therapies},
  journal = {Cancer Drug Resistance},
  year = {2026},
  doi = {10.20517/cdr.2025.213}
}
Kostenlos starten →